Global prevalence of non-alcoholic fatty liver disease in type 2 diabetes mellitus: an updated systematic review and meta-analysis

Gut, Journal Year: 2023, Volume and Issue: 72(11), P. 2138 - 2148

Published: July 25, 2023

Non-alcoholic fatty liver disease (NAFLD) is the leading cause of chronic disease, with type 2 diabetes mellitus (T2DM) as a major predictor. Insulin resistance and inflammation are key pathways in pathogenesis T2DM to NAFLD vice versa, synergistic effect increasing morbidity mortality risks. This meta-analysis aims quantify prevalence clinically significant advanced fibrosis people T2DM.MEDLINE Embase databases were searched from inception until 13 February 2023. The primary outcomes NAFLD, non-alcoholic steatohepatitis (NASH) T2DM. A generalised linear mixed model Clopper-Pearson intervals was used for analysis proportions sensitivity conducted explore heterogeneity between studies.156 studies met inclusion criteria, pooled 1 832 125 patients determined that rates NASH 65.04% (95% CI 61.79% 68.15%, I2=99.90%) 31.55% 17.12% 50.70%, I2=97.70%), respectively. 35.54% 19.56% 55.56%, I2=100.00%) individuals had (F2-F4), while 14.95% 11.03% 19.95%, I2=99.00%) (F3-F4).This study high Increased efforts required prevent combat rising burden NAFLD.CRD42022360251.

Language: Английский

---

Longitudinal Outcomes Associated With Metabolic Dysfunction-Associated Steatotic Liver Disease: A Meta-analysis of 129 Studies

Clinical Gastroenterology and Hepatology, Journal Year: 2023, Volume and Issue: 22(3), P. 488 - 498.e14

Published: Sept. 28, 2023

Language: Английский

---

Concordance between metabolic dysfunction‐associated steatotic liver disease and nonalcoholic fatty liver disease

Hepatology Research, Journal Year: 2024, Volume and Issue: 54(6), P. 600 - 605

Published: Jan. 17, 2024

A multisociety consensus group proposed a new nomenclature for metabolic dysfunction-associated steatotic liver disease (MASLD). Although patients with nonalcoholic fatty (NAFLD) are expected to be reclassified as MASLD under the nomenclature, concordance between and NAFLD remains unclear. Moreover, waist circumference could adjusted by ethnicity diagnosing MASLD; however, there limited data on optimal in Japanese population.

Language: Английский

---

Long‐term clinical outcomes in steatotic liver disease and incidence of liver‐related events, cardiovascular events and all‐cause mortality

Alimentary Pharmacology & Therapeutics, Journal Year: 2024, Volume and Issue: 60(1), P. 61 - 69

Published: April 25, 2024

Summary Background A multi‐society consensus group proposed a new nomenclature for steatotic liver disease (SLD) including metabolic‐dysfunction associated (MASLD), MASLD and increased alcohol intake (MetALD) alcohol‐associated (ALD). However, the risk of liver‐related events, major adverse cardiovascular events (MACE) all‐cause mortality among various sub‐groups is unknown. Aims To evaluate MACE death patients with SLD. Methods We conducted nationwide, population‐based study enrolled 761,400 diagnosed MASLD, MetALD or ALD. The primary endpoint was occurrence in Results cumulative incidence were highest ALD, followed by ( p < 0.001 both death), while ALD 0.001). Using as reference adjusting age, sex, smoking, diabetes mellitus, dyslipidaemia hypertension, adjusted hazard ratios (95% confidence intervals) 1.42 (1.1–1.8), 0.68 (0.63–0.73) 1.13 (0.98–1.3), respectively. In they 3.42 (2.6–4.6), 0.58 (0.49–0.67) 1.60 (1.3–2.0), respectively, death. Conclusions can be used to stratify complications prognosis. beneficial stratification identifying mechanisms disease‐specific therapeutic implications.

Language: Английский

---

Glycemic control target for liver and cardiovascular events risk in metabolic dysfunction‐associated steatotic liver disease

Hepatology Research, Journal Year: 2024, Volume and Issue: 54(8), P. 753 - 762

Published: Feb. 24, 2024

Abstract Aims Optimizing glycemic control may prevent liver‐related events and major adverse cardiovascular (MACE) in patients with metabolic dysfunction‐associated steatotic liver disease (MASLD). However, the optimal hemoglobin A1c (HbA1c) threshold associated a lower risk of complications, particularly as well MACE is unknown. Methods We investigated nationwide population‐based cohort identified 633 279 MASLD, mean follow‐up 4.2 years. Hemoglobin levels were measured annually. The primary endpoint was to determine HbA1c level complications. Results Mean (per 1%) (subdistribution hazard ratio [sHR] 1.26; 95% confidence interval [CI], 1.12–1.42) (sHR 1.36; CI, 1.32–1.41) after adjustment for confounders. Multivariable sHR (95% CI) <5.0%, 6.0%–6.9%, 7.0%–7.9%, 8.0%–8.9%, ≥9.0% (reference, 5.0%–5.9%) 14 (9.1–22), 1.70 (1.2–2.3), 3.32 (2.3–4.8), 3.81 (2.1–6.8), 4.83 (2.4–9.6) events, 1.24 (0.8–1.8), 1.27 (1.2–1.4), (1.5–2.0), 2.36 (1.9–2.9), 4.17 (3.5–5.0) MACE. An 7% selected predicting complications 2.40 [1.8–3.2] 1.98 [1.8–2.2] MACE). Conclusion increased dose‐dependent fashion an increase levels, except <5.0% events. be utilized target MASLD.

Language: Английский

---

Natural history of lean and non-lean metabolic dysfunction-associated steatotic liver disease

Journal of Gastroenterology, Journal Year: 2024, Volume and Issue: 59(6), P. 494 - 503

Published: April 4, 2024

Language: Английский

---

Cardiometabolic criteria as predictors and treatment targets of liver‐related events and cardiovascular events in metabolic dysfunction‐associated steatotic liver disease

Alimentary Pharmacology & Therapeutics, Journal Year: 2024, Volume and Issue: 60(8), P. 1033 - 1041

Published: Aug. 8, 2024

The diagnosis of metabolic dysfunction-associated steatotic liver disease (MASLD) requires at least one five cardiometabolic criteria. It is unclear whether these criteria can be used as predictors and treatment targets for complications including liver-related events major adverse cardiovascular (MACE).

Language: Английский

---

FIB-4 Predicts MACE and Cardiovascular Mortality in Patients With Nonalcoholic Fatty Liver Disease

Canadian Journal of Cardiology, Journal Year: 2022, Volume and Issue: 38(11), P. 1779 - 1780

Published: Aug. 3, 2022

Language: Английский

---

Prevalence and associated metabolic factors of nonalcoholic fatty liver disease in the general population from 2014 to 2018 in Japan: A large‐scale multicenter retrospective study

Hepatology Research, Journal Year: 2023, Volume and Issue: 53(11), P. 1059 - 1072

Published: Aug. 4, 2023

Abstract Aim The prevalence of nonalcoholic fatty liver disease (NAFLD) is increasing worldwide. aim this study was to determine the recent and clinical characteristics NAFLD in Japan. Methods This initially included 410 061 retrospectively enrolled adults from medical health checkup registry for metabolic syndrome, chronic kidney disease, Japan (MIRACLE‐J; UMIN‐CTR no. UMIN000049419), who were evaluated between 2014 2018 at 13 centers Individuals consuming >20 g alcohol/day or with excluded. Fatty diagnosed by ultrasonography. probability advanced fibrosis estimated based on fibrosis‐4 index score. Results A total 71 254 participants final analysis. overall 25.8%. There a significant, twofold difference men (37.4%) women (18.1%). Nonalcoholic increased linearly body mass index, triglycerides, low‐density lipoprotein cholesterol regardless threshold values, even absence obesity. Among patients NAFLD, 14% had diabetes mellitus, 31% hypertension, 48% dyslipidemia. 1.7% 1.0% according score, respectively. Conclusions approximately one‐quarter general population linear relationship various parameters, nonobese participants. be 1%–2%.

Language: Английский

---

Position paper on perioperative management and surgical risk in the patient with cirrhosis

Revista de Gastroenterología de México (English Edition), Journal Year: 2024, Volume and Issue: 89(3), P. 418 - 441

Published: July 1, 2024

Management of the patient with cirrhosis liver that requires surgical treatment has been relatively unexplored. In Mexico, there is currently no formal stance or expert recommendations to guide clinical decision-making in this context. The present position paper reviews existing evidence on risks, prognoses, precautions, special care, and specific management procedures for patients require interventions invasive procedures. Our aim provide by an panel, based best published evidence, consequently ensure timely, quality, efficient, low-risk care group patients. Twenty-seven were developed address preoperative considerations, intraoperative settings, postoperative follow-up care. assessment major should be overseen a multidisciplinary team includes anesthesiologist, hepatologist, gastroenterologist, nutritionist. With respect decompensated patients, nephrology specialist may required, given kidney function also parameter involved prognosis these El terreno del paciente con cirrosis que requiere de una intervención quirúrgica ha sido poco explorado. En México, la fecha contamos un posicionamiento o recomendaciones expertos ayuden toma decisiones clínicas en este contexto. Revisar evidencia existente sobre el riesgo, pronóstico, precauciones, cuidados especiales y manejo proceder específico para los pacientes requieren ser intervenidos quirúrgicamente mediante procedimientos invasivos, emitir por panel experto, basadas mejor publicada atención oportuna, calidad, eficiente menor riesgo posible grupo pacientes. Se obtuvieron 27 recomendaciones, donde se abordan preoperatorio, escenario transoperatorio seguimiento postoperatorios. La valoración cuidado procedimiento quirúrgico invasivo mayor, debe estar cargo equipo multidisciplinario brinde soporte al cirujano, durante todo perioperatorio, incluir anestesiólogo, hepatólogo, gastroenterólogo, nutriólogo clínico. descompensado, puede necesario involucrar especialistas nefrología ya función renal es parámetro implicado también pronóstico estos

---